NasdaqGM:NAMSBiotechs
How EMA Validation of Obicetrapib and Manufacturing Expansions Will Impact NewAmsterdam Pharma (NAMS) Investors
NewAmsterdam Pharma announced that the European Medicines Agency has validated the Marketing Authorization Application for obicetrapib, targeting primary hypercholesterolemia, following positive Phase 3 trial results and new supply and manufacturing collaborations with Menarini and Piramal Pharma Solutions.
This regulatory milestone is paired with expanded commercial manufacturing capabilities in the US and India, indicating operational preparedness for future product launches in...